RBC Capital Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $30

Benzinga Newsdesk www.benzinga.com Negative 93.3%

Neg 93.3% Neu 0% Pos 0%

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price target from $42 to $30.